Podcast
#08: Safety measures for blood products for Sars-CoV-2
Duration: 20 minutes
- With more than 100 million COVID-19 cases worldwide, what’s the impact on our blood supply?
- What’s the risk of transfusion-transmitted infection? Is COVID-19 convalescent plasma (CCP) safe?
- Which treatments be applied to blood products in order to ensure safety for the patient?
Let Dr. Ray Goodrich answer these hard questions. He’s a leading expert in infectious disease and transfusion medicine, as well as the inventor of a world-leading pathogen reduction technology. He’ll provide the background, evidence and answers we need as the virus continues to spread and use of CCP increases around the world.
This educational podcast activity is brought to you by Ortho Clinical Diagnostics, Inc., and is not certified for continuing medical education. Ortho Clinical Diagnostics, Inc. sponsors the program, and the speaker must present information following applicable FDA requirements
About Our Speaker:
About Our Speaker:
Dr. Raymond P. Goodrich
Executive Director of the IDRC; Professor, Department of Microbiology, Immunology and Pathology
Colorado State University
Dr. Raymond P. Goodrich, is the Executive Director of the Infectious Disease Research Center and a professor of Immunology and Pathology in the Department of Microbiology at Colorado State University. His research group is currently focused on methods to safeguard blood transfusion products and to create and rapidly produce novel vaccine formulations that can be used to address infectious diseases.
Dr. Raymond P. Goodrich, is the Executive Director of the Infectious Disease Research Center and a professor of Immunology and Pathology in the Department of Microbiology at Colorado State University. His research group is currently focused on methods to safeguard blood transfusion products and to create and rapidly produce novel vaccine formulations that can be used to address infectious diseases.
READING MATERIALS
Janna M. Mundt, Lindsay Rouse, Jeroen Van den Bossche and Raymond P. Goodrich Chemical and Biological Mechanisms of Pathogen Reduction Technologies Photochemistry and Photobiology (2014) DOI: 10.1111/php.12311
Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Systematic Review (2017);7:CD009072
Frédéric Garban, Audrey Guyard , Helene Labussière , Claude-Eric Bulabois, et al. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. JAMA Oncology; (2018); 4(4):468-475. doi: 10.1001/jamaoncol.2017.5123.
Rebulla P, Garban F, van der Meer PF, Heddle NM, McCullough J. A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets.Transfusion (2020);60(6):1267-1277. doi: 10.1111/trf.15791. Epub 2020 Apr 23
Bah A, Cardoso M, Seghatchian J, Goodrich RP.Reflections on the dynamics of bacterial and viral contamination of blood components and the levels of efficacy for pathogen inactivation processes. Transfusion and Apheresis Science (2018);57(5):683-688. doi: 10.1016/j.transci.2018.09.004. Epub 2018 Sep 11
Lisette Hauser 1, Anne-Marie Roque-Afonso, Alexandre Beylouné, Marion Simonet, Bénédicte Deau Fischer, Nicolas Burin des Roziers, Vincent Mallet, Pierre Tiberghien, Philippe Bierling Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood (2014); 30;123(5):796-7. doi: 10.1182/blood-2013-09-524348.
Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S.
Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial.Lancet (2016); 23;387(10029):1753-61. doi: 10.1016/S0140-6736(16)00581-X.
Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion-transmitted infections in sub-Saharan Africa. Transfusion. (2010);50(2):433-42. doi: 10.1111/j.1537-2995.2009.002402.x. Epub 2009 Oct 15.PMID: 19843290
Mirasol Evaluation of Reduction in Infections Trial (MERIT). NCT03737669. www.clinicaltrials.gov.
Goodrich, R.P., Ignorance Is Not Bliss. Transfusion. (2018);58(3):615-616. doi: 10.1111/trf.14486
Tiffany Thomas, Davide Stefanoni, Monika Dzieciatkowska, Aaron Issaian, Travis Nemkov, Ryan C Hill, Richard O Francis, Krystalyn E Hudson, Paul W Buehler, James C Zimring, Eldad A Hod,Kirk C Hansen, Steven L Spitalnik, Angelo D'Alessandro Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients. MedRXIV (2020) doi: https://doi.org/10.1101/2020.06.29.20142703
Boumaza, A., Gay, L., Mezouar, S., Diallo, A.B. Monocytes and Macrophages, targets of SARS-CoV-2: The clue for COVID-19 immunoparlysis. BioRXiv (2020); doi: https://doi.org/10.1101/2020.09.17.300996
Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. PLoS One. (2020); 29;15(5):e0233947. doi: 10.1371/journal.pone.0233947.
https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
https://www.history.com/news/blood-plasma-covid-19-measles-spanish-flu
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, et. al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. (2020); 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020
Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C. Transfusion and Apheresis Science. (2011) ;44(1):25-31. doi: 10.1016/j.transci.2010.12.005. Epub 2011 Jan 19
Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19) ; Interim guidance, WHO 20 March 2020
FDA Investigational COVID-19 Convalescent Plasma - Emergency INDs March 24, 2020
EU programme of COVID-19 convalescent plasma collection and transfusion EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY; April 8, 2020; https://www.isbtweb.org/working-parties/global-blood-safety/
